Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 220

Similar articles for PubMed (Select 22449349)

1.

Recent advances and prognosis in idiopathic membranous nephropathy.

Segal PE, Choi MJ.

Adv Chronic Kidney Dis. 2012 Mar;19(2):114-9. doi: 10.1053/j.ackd.2012.01.007. Review.

PMID:
22449349
2.

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.

Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA.

J Am Soc Nephrol. 2014 Jun;25(6):1357-66. doi: 10.1681/ASN.2013040430. Epub 2014 Mar 7.

3.

Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.

Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA.

Kidney Int. 2012 Oct;82(7):797-804. doi: 10.1038/ki.2012.209. Epub 2012 Jun 6.

PMID:
22673885
4.

[Membranous glomerulonephritis: better therapy with autoantibody monitoring?].

Stahl RA, Hoxha E, Helmchen U.

Dtsch Med Wochenschr. 2011 Aug;136(34-35):1733-7. doi: 10.1055/s-0031-1286067. Epub 2011 Aug 29. Review. German.

PMID:
21877306
5.

Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.

Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS.

PLoS One. 2013 Apr 26;8(4):e62151. doi: 10.1371/journal.pone.0062151. Print 2013.

6.

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z.

J Am Soc Nephrol. 2011 Jun;22(6):1137-43. doi: 10.1681/ASN.2010090967. Epub 2011 May 12.

7.

Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.

Bech AP, Hofstra JM, Brenchley PE, Wetzels JF.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1386-92. doi: 10.2215/CJN.10471013. Epub 2014 Jul 17.

PMID:
25035272
8.

Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.

Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H.

Nephrol Dial Transplant. 2013 Jul;28(7):1839-44. doi: 10.1093/ndt/gfs439. Epub 2012 Dec 6.

9.

M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.

Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1883-90. doi: 10.2215/CJN.03850414. Epub 2014 Sep 29.

PMID:
25267554
10.

Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.

Schlumberger W, Hornig N, Lange S, Probst C, Komorowski L, Fechner K, Dähnrich C, Stöcker W.

Autoimmun Rev. 2014 Feb;13(2):108-13. doi: 10.1016/j.autrev.2013.09.005. Epub 2013 Sep 26.

11.

Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy.

Huang X, Qin W, Zhang M, Zheng C, Zeng C, Liu Z.

Am J Med Sci. 2013 Jul;346(1):32-7. doi: 10.1097/MAJ.0b013e318267b5cd.

PMID:
23103439
12.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF.

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. Epub 2012 Sep 6.

13.

The pathogenesis of membranous nephropathy: evolution and revolution.

Glassock RJ.

Curr Opin Nephrol Hypertens. 2012 May;21(3):235-42. doi: 10.1097/MNH.0b013e3283522ea8. Review.

PMID:
22388552
14.

Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

Hofstra JM, Wetzels JF.

Neth J Med. 2012 Apr;70(3):109-13. Review.

15.

Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.

Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q.

J Am Soc Nephrol. 2015 Feb;26(2):291-301. doi: 10.1681/ASN.2013121315. Epub 2014 Sep 9.

PMID:
25205735
16.

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE.

Kidney Int. 2013 May;83(5):940-8. doi: 10.1038/ki.2012.486. Epub 2013 Jan 30.

PMID:
23364522
17.

Pathogenesis of membranous nephropathy: update.

Kwatra IS, Prasher PK.

J Assoc Physicians India. 2013 Nov;61(11):807-10. Review.

PMID:
24974493
18.

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.

Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VL.

Nephrol Dial Transplant. 2014 Dec;29(12):2334-42. doi: 10.1093/ndt/gfu252. Epub 2014 Jul 25.

PMID:
25063424
19.

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.

20.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ.

J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk